Related references
Note: Only part of the references are listed.Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
Naoto Takahashi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy
Delphine Rea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Second Tyrosine Kinase Inhibitor Discontinuation Attempt in Patients With Chronic Myeloid Leukemia
Laurence Legros et al.
CANCER (2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus et al.
ANNALS OF ONCOLOGY (2017)
Does the Frequency of Molecular Monitoring After Tyrosine Kinase Inhibitor Discontinuation Affect Outcomes of Patients With Chronic Myeloid Leukemia?
Jee Hyun Kong et al.
CANCER (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Nobuko Hijiya et al.
BLOOD (2016)
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P. Hughes et al.
BLOOD (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The concept of treatment-free remission in chronic myeloid leukemia
S. Saussele et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Silvia Mori et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Managing pregnancy in chronic myeloid leukaemia
Renuka Palani et al.
ANNALS OF HEMATOLOGY (2015)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
Susanne Saussele et al.
BLOOD (2015)
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Johan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Imatinib Cessation in Children and Adolescents With Chronic Myeloid Leukemia in Chronic Phase
Frederic Millot et al.
PEDIATRIC BLOOD & CANCER (2014)
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib
Sung-Eun Lee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Susan Branford et al.
BLOOD (2012)
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
Gabriele Gugliotta et al.
BLOOD (2011)
Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
John M. Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour et al.
BLOOD (2006)
Share Paper
